LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral anti-diabetic agents that improve glycemic control by inhibiting SGLT2-mediated renal glucose reabsorption. Currently available agents increase urinary glucose excretion (UGE) to <50% of maximal values because they do not i...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Pharmacol Res Perspect
Huvudupphovsmän: Powell, David R, Smith, Melinda G, Doree, Deon D, Harris, Angela L, Xiong, Wendy W, Mseeh, Faika, Wilson, Alan, Gopinathan, Suma, Diaz, Damaris, Goodwin, Nicole C, Harrison, Bryce, Strobel, Eric, Rawlins, David B, Carson, Ken, Zambrowicz, Brian, Ding, Zhi-Ming
Materialtyp: Artigo
Språk:Inglês
Publicerad: BlackWell Publishing Ltd 2015
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4448982/
https://ncbi.nlm.nih.gov/pubmed/26038705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.129
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk